Numerate Completes $4 Million Series A

Numerate, a biotechnology company leveraging a novel drug engineering process to design lead-stage drug compounds, announced today that it has completed a $4 million Series A.
From what I can tell, the company is working on the holy grail of in silico drug discovery. Add some inputs, out comes the list of compounds to synthesize. [...]

Zafgen Raises $14 Million in Series B

ZafGen, a Cambridge-based developer of an obesity therapy based on the vascular targeting of adipose tissue, has raised $14 million in Series B funding, according to a regulatory filing. Third Rock Ventures was joined by return backer Atlas Venture. The company previously raised around $5.2 million from Atlas and GreatPoint Ventures.
Interesting play here. There [...]

Accera Completes $35 Million Series C Financing

Accera announced it has recently closed a Series C financing round of $35 million (euro 27 million), led by Inventages Venture Capital SA. The company says that the proceeds of this financing will be used to begin sales and marketing ofthe company’s lead product, Axona(TM) (previously known as Ketasyn), which as the company says, is [...]

ArQule and Daiichi Sankyo Ink c-Met and Discovery Deals

ArQule and Daiichi Sankyo announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. One agreement covers the license of ARQ 197 and the other is an R&D agreement.
ARQ 197 is a phase 2 stage, selective inhibitor of c-Met, [...]

Precision Therapeutics Secures $43 Million in VC Funding

Precision Therapeutics has secured $43 million in additional funding to expand the development and commercialization of ChemoFx(R). ChemoFx is a diagnostic test that helps physicians select the most effective chemotherapeutic regimen for cancer patients. New investor, Longitude Venture Partners, L.P., led the round and was joined by existing investors Adams Capital Management, Quaker BioVentures, Birchmere [...]

Fidelity Biosciences Takes Over EnVivo Pharmaceuticals

Fidelity Biosciences has injected $65 million into EnVivo Pharmaceuticals Inc. and bought out all other venture investors in the neurological-drug developer.
EnVivo Pharmaceuticals was founded in 2001 and currently has 38 FTEs. EnVivo had raised ~$63.2M in three funding rounds, $14.9M Series A in October 2002 and $24.3M Series B in September 2004, $24M Series C [...]

Salient Surgical Technologies Nets A $17.9M Series F

Salient Surgical Technologies, developer of advanced energy devices for use in surgical procedures, announced the completion of its Series F financing totaling $17.9 million. Investors in the round included Piper Jaffray, Arnerich Massena & Associates, Medtronic, Inc., RiverVest Venture Partners, and other financial and strategic investors.
Salient plans to use the net proceeds to fund programs [...]

DFine Secures $30 Million in Series D Funding

DFine, developer of
minimally invasive solutions for treating vertebral compression fractures
(VCFs), has secured a $30 million round of investment in its Series D
funding led by BBT Fund LP and Highland Capital Management. Other investors
include Prospect Venture Partners and Vanguard Ventures.
DFine is dedicated to developing treatments for VCFs that relieve pain
and improve quality of life for patients. [...]

Weekly Biopharm Financing: Cardiome, Genomic Vision, RF Surgical, NuPathe, Cell and Cara Tharapeutics

NuPathe (Business Wire)
Raised $30 million in a Series B, private stock sale. They will mainly use the funds to support the phase 3 trial of their sumatriptan patch for migraine but some money will get funneled into their Parkinson’s
Cardiome (PRNewswire)
Under the non-brokered private placement, Cardiome has entered into an agreement to sell 2,272,727 Series [...]

Funding Roundup: Genfit, Microchip Biotech and Xlumena

Image via Wikipedia

Hot start to the week on the funding side and on the thermometer (as I write this, it’s closing in on 101F in Boston).
XLumena raises $6.15M for endoscopic devices (VentureWire)
Microchip Biotechnologies, Inc. Nears $15M in New Funding (BioSpace)
GENFIT Secures €7.1 Million Funding from Oseo (BioSpace)

NanoHorizons Wins Second Funding Round

Image via Wikipedia

NanoHorizons announced that it has raised approximately $6.7 million in a second round of funding from Penn Venture Partners, L.P., Life Sciences Greenhouse of Central Pennsylvania, and a bunch of other private investors. Half of the investments have been funded, with the remainder to be funded (subject to attaining certain milestones) within one [...]